<DOC>
	<DOCNO>NCT02161783</DOCNO>
	<brief_summary>This guideline treatment graft failure hematopoietic stem cell transplant ( HSCT ) . This regimen , consist cyclophosphamide fludarabine low dose total body irradiation ( TBI ) design promote donor engraftment day 42 initial graft failure . The graft consist bone marrow G-CSF mobilized peripheral blood haploidentical related donor . The source stem cell determine transplant team base factor patient 's age , medical history , donor availability accord current University Minnesota Blood Marrow Transplantation Program selection guideline .</brief_summary>
	<brief_title>Treatment Graft Failure After Hematopoietic Stem Cell Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>Patients primary secondary graft failure , define , may receive second transplant : Primary graft failure define achieve ANC ≥0.5x10^9/L three consecutive day day 35 42 follow first transplant . Secondary graft failure define achieve ANC ≥0.5x10^9/L three consecutive day day 35 42 , subsequently drop 0.5x10^9/L without recovery . Loss chimerism define achieve ANC ≥0.5x10^9/L three consecutive , less 10 % CD15+ donor cell marrow peripheral blood . Recipients acceptable organ function define : Renal : creatinine &lt; 2.0 ( adult ) creatinine clearance &gt; 30 . For creatinine clearance &lt; 70 , consultation BMT pharmacist necessary chemotherapy dose adjustment . Hepatic : bilirubin , AST/ALT , ALP &lt; 10 x upper limit normal Cardiac : leave ventricular ejection fraction &gt; 40 % Uncontrolled infection time transplant . Patients Fanconi Anemia DNA breakage syndrome .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Hematopoietic stem cell transplant</keyword>
</DOC>